The Development of CAR-T Immunotherapy
DOI:
https://doi.org/10.54097/ijbls.v4i3.05Keywords:
CAR-T Cell Therapy, Tumor, Immunotherapy, Drug DevelopmentAbstract
With the advancement of tumor biology, molecular biology and cell biology, the treatment of cancer has been greatly promoted. So many scientific researches have given messages that new tumor immunotherapy methods such as CAR-T cell immunotherapy have become another new type of treatment can replace targeted therapy, cancer surgery, radiotherapy, and chemotherapy This paper focuses on the development prospect, research progress and research problems of CAR-T cell immunotherapy. Meantime, the advantages, martyrs and differences of various immunotherapies were compared, which provided reference for the research and preparation of tumor immunotherapy drugs. This review will review contemporary and recent major research on CAR T cells, with a focus on overcoming the adverse effects of CAR-T therapy and exploring new treatments
Downloads
References
Fang, W. (2019). New vaccines attack cancer cells in the body. Health and Life, 15(1).
Ji, Y., Bai, C., Li, D., et al. (2007). Recurrence and reoperation of giant cell tumor of tendon sheath in hand. Chinese Journal of Hand Surgery, 023(003): 148.
Ma, B., Fan, Q., Zhang, H., et al. (1999). Inhibitory effect of chemotherapeutic drugs on the growth of cultured chordoma cells. Journal of Military Medical University, 12: 3.
Zeng, Q., Ouyang, W., Huang, Y., et al. (2020). Discussion on the role and significance of traditional Chinese medicine and immunotherapy in tumor treatment. World Medical Information Abstracts, 23: 151-153.
Guo, Z. (2002). The role of Fas, IFN-γ and MHC Class Ⅱ Molecules in the activation or death of dendritic cells and the related mechanisms. Thesis of Second Military Medical University, 1: 1-61.
Song, H. (2018). Preparation of injectable hydrogel tumor vaccine and study on its immunotherapy effect. Thesis of Peking Union Medical College, 2: 1-132.
McHayleh, W., Bedi, P., Sehgal, R., et al. (2019). Chimeric antigen receptor T-Cells: The future is now. Clin Med., 8: 207.
Qiu, Q., et al. (2016). Study on the specific inhibition of small peptide-ScFv αvβ3 conjugate on the growth of lung cancer cells in vivo and in vitro. Am J Cancer Res., 6(12):2846-2858.
Maude, S.L., Laetsch, T.W., Buechner, J., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. Engl J Med., 378:439-448.
Hay, K.A., Hanafi, L.A., Li, D., et al. (2017). Kinetics and biomarkers of severe cytokine release syndrome after CD19chimeric antigen receptor-modified T-cell therapy. Blood, 130: 2295-2306.
Lee, D.W., Gardner, R., Porter, D.L., et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2): 188-195.
Dale, R.C. (2016). Interleukin-6 blockade as rescue therapy in autoimmune encephalitis. Neurotherapeutics, 13: 821-823.
Hercus, T.R., Dhagat, U., Kan, W.L., et al. (2013). Signalling by the betac family of cytokines. Cytokine Growth Factor Rev., 24(1): 189-201.
Wicks, I.P., Roberts, A.W. (2016). Targeting GM-CSF in inflammatory diseases. Nat Reviews Rheumatol., 12(1): 37-48.
Schuster, S.J., Svoboda, J., Chong, E., et al. (2017). Chimeric antigen receptor T Cells in refractory B-Cell lymphomas. New England Journal of Medicine, 377(26): 2545-54.
Abreu, T.R., Fonseca, N.A., Goncalves, N., et al. (2020). Current challenges and emerging opportunities of CAR-T cell therapie. Journal of Control Release, 319(1): 246-261.
Karschnia P, Jordan J T, Forst D A, et al. (2019). Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
